Form 8-K

8-K — Paysign, Inc.

Accession: 0001683168-26-005988

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001496443

SIC: 7389 (SERVICES-BUSINESS SERVICES, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — paysign_8k.htm (Primary)

EX-99.1 — EARNINGS RELEASE (paysign_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: paysign_8k.htm · Sequence: 1

Paysign, Inc. 8-K

false

0001496443

2026-08-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 5, 2026

PAYSIGN,

INC.

(Exact name of registrant as specified in its charter)

Nevada

001-38623

95-4550154

(State or other jurisdiction of incorporation)

(Commission file number)

(I.R.S. Employer Identification Number)

2615 St. Rose Parkway

Henderson, Nevada 89052

(Address of principal executive offices) (Zip Code)

(702) 453-2221

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material

pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PAYS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2026, we issued

a press release regarding our financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished herewith

as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

As provided in General Instruction

B-2 of SEC Form 8-K, the information set forth in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as

amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set

forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release entitled “Paysign Reports Record Second Quarter

2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PAYSIGN, INC.

Date: August 5, 2026

By: /s/ Mark Newcomer

Mark Newcomer, President and

Chief Executive Officer

EX-99.1 — EARNINGS RELEASE

EX-99.1

Filename: paysign_ex9901.htm · Sequence: 2

Exhibit 99.1

Earnings Release

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million,

Up 48%; Raises Full-Year Outlook

Growth Driven by Continued Momentum in Plasma and Patient Affordability

Businesses

Mix Shift and Expense Discipline Continue to Drive Gross and Operating

Margin Expansion

Balance Sheet Supports Continued Investment and Growth Initiatives

HENDERSON, Nev. – August 5, 2026 – (Business Wire) –

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and

management platforms and integrated payment processing for the life sciences industries, today announced financial results for the second

quarter 2026.

Second Quarter 2026 Financial Highlights

Revenues of $28.25 million in Q2’26, up 48.1% from Q2’25

Pharma revenue increased to $14.65 million in Q2’26, an increase of 88.9% versus Q2’25; added 51 net patient affordability programs during the past 12 months, exiting the quarter with 148 active programs

Plasma revenue increased to $13.04 million in Q2’26, an increase of 21.4% versus Q2’25; total net plasma center count decreased by 46 during the past 12 months, exiting the quarter with 561 centers.

Gross profit margin was 63.3% in Q2’26 compared to 61.6% in Q2’25

Operating margin increased to 24.8% in Q2’26, up from 7.5% from Q2’25; excluding the fair value adjustment on contingent consideration, operating margin increased to 21.3%1

GAAP net income of $6.76 million, or $0.11 per fully diluted share, in Q2’26 versus GAAP net income of $1.39 million, or $0.02 per fully diluted share in Q2’25

Adjusted EBITDA of $9.61 million in Q2’26, up 113.0% from $4.51 million for Q2’25; diluted Adjusted EBITDA per share of $0.16 versus $0.08 for Q2’251

Exited the quarter with $27.37 million of unrestricted cash and zero bank debt

Second quarter 2026 gross dollar load volume was up 24.3% versus second quarter 2025

Second quarter 2026 gross spend volume was up 24.2% versus second quarter 2025

Raising full-year 2026 outlook – revenue $114.0 million to $117.0 million; Adjusted EBITDA $35.0 million to $38.0 million

1Adjusted EBITDA, Adjusted EBITDA per share, and

Adjusted operating margin are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation

of net income to Adjusted EBITDA and operating income margin to Adjusted operating margin at the end of the press release.

“Paysign delivered a strong second quarter, achieving record

revenue, net income, and adjusted EBITDA while continuing to expand margins,” said Mark Newcomer, President and CEO of Paysign.

“Strong growth in our patient affordability business, steady performance in plasma donor compensation, and disciplined execution

across the company drove meaningful operating leverage and profitability, reinforcing the multiyear strategy we have been building. With

momentum across the business and a robust pipeline of opportunities, we intend to remain focused on sustainable growth, continued margin

expansion, and creating long-term value for shareholders.”

2026 Second Quarter Results

Total revenues increased 48.1%, or $9.17 million, to $28.25 million,

up from $19.08 million in the second quarter of 2025. Pharma industry revenue increased 88.9% to $14.65 million from $7.75 million due

to the financial benefit of 51 net pharma patient affordability programs launched during the past 12 months, and a corresponding increase

in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and customer

service contact center support. Processed claims increased by approximately 54% compared to the second quarter of 2025. Plasma revenue

increased 21.4% to $13.04 million, up from $10.74 million, primarily due to an increase in plasma donations and dollars loaded to cards,

offset by the reduction of 46 net plasma centers during the past 12 months. The decline in net plasma centers reflected customer center

closures and the sale of certain customer centers to a company that uses another provider. The average monthly revenue per center increased

to $7,699 versus $7,098 and the average number of loads per center increased, representing stronger utilization at existing centers. We

exited the quarter with 561 centers versus 607 centers in the second quarter of 2025.

Cost of revenues increased 41.4% to $10.36 million due to related costs

associated with the growth in our businesses including network and related costs, call center support costs, a new customer service contact

center that went live in November 2025 and higher employee costs. Gross profit margin improved to 63.3% compared to 61.6% in the second

quarter of 2025 as we experienced a greater mix of pharma revenue.

Total operating expenses were $10.89 million compared to $10.32 million

in the second quarter of 2025, an increase of 5.5%. During the quarter, we recorded as a reduction to selling, general and administrative

expense a one-time, non-cash fair value adjustment on contingent consideration of $990,000 related to our Gamma acquisition. Excluding

this benefit, total operating expenses would have been $11.9 million, an increase of 15.1% over the prior year. Selling, general and administrative

expenses increased by 4.3% to $8.55 million. Of that amount, stock compensation expense increased 31.2% to $1.25 million. Depreciation

and amortization increased by $219 thousand, or 10.4%, due mainly to the amortization of intangible assets from our Gamma acquisition

and continued capitalization of new software development costs and equipment purchases related to the enhancement to our processing platform.

Operating margin was 24.8% compared to 7.5% in the second quarter of 2025. Excluding the gain on contingent consideration, operating margins

would have been 21.3%.

The company recorded an income tax provision of $1.15 million, resulting

in an effective tax rate of 14.5%. This was an increase from the $655 thousand provision recorded during the same period last year where

the effective tax rate was 32.1%. The effective tax rates reflect adjustments for discrete quarterly items and tax benefits from stock-based

compensation. The significant driver in the discrete item adjustment in the second quarter of 2026 was primarily related to the increase

in stock price at June 30, 2026, when compared to the same period in the prior year.

Net income for the quarter totaled $6.76 million, or $0.11 per fully

diluted share, an increase of 386.9% from $1.39 million, or $0.02 per fully diluted share, reported in the second quarter of 2025. On

a non-GAAP basis, EBITDA, defined as earnings before interest, taxes, depreciation and amortization, increased by $5.79 million, or 162.8%,

to $9.35 million. Adjusted EBITDA, which excludes stock-based compensation and change in fair value of contingent consideration from EBITDA

and is used by management to evaluate core operating performance, rose $5.10 million, or 113.0%, to $9.61 million, or $0.16 per fully

diluted share.

Balance Sheet at June 30, 2026

The company’s unrestricted and restricted cash balances increased

by a combined $11.50 million from December 31, 2025, largely related to the improvement in our operating results, growth of existing customer

programs and the launch of new customer programs.

During the six months ended June 30, 2026, unrestricted cash increased

by $6.31 million to $27.37 million. The increase was attributable to net income, non-cash adjustments, and the timing of operating assets

and liability payments, partially offset by capital investments in intangible and fixed assets and payments of other liabilities associated

with the Gamma acquisition.

Restricted cash increased $5.19 million to $149.11 million from December

31, 2025, primarily related to an increase in funds on card of $7.41 million offset primarily by a decrease in customer program deposits

for our plasma and pharma customers of $2.22 million. Restricted cash represents funds used for customer card funding and pharmaceutical

claim reimbursements with a corresponding offset under current liabilities.

2026 Outlook

“We delivered another strong quarter, with results in both plasma

and patient affordability reflecting the momentum we have been building,” commented Jeff Baker, Chief Financial Officer of Paysign.

“Our first two quarters of 2026 make two things clear: our patient affordability solutions continue to resonate with pharmaceutical

companies, and recent trends in our plasma business indicate improvement from the high inventory levels that weighed on results throughout

2025. We also drove year-over-year improvement across our core margin metrics, even excluding a one-time, non-cash benefit of $990,000

related to the fair value of the Gamma acquisition earn-out liability. Revenue, operating margin and net income all finished above the

high end of our guidance, and the strength we’ve seen through the first half of the year, combined with the visibility into additional

program launches and seasonal trends, supports our increased full-year outlook.”

Third Quarter 2026

Full Year 2026

Revenue

$28.5M – $30.0M

$114.0M – $117.0M

Revenue growth (YoY)

32.0% – 38.9%

39.0% – 43.0%

Gross margin

61.0% – 63.0%

62.0% – 63.0%

Net income

$5.7M – $6.0M

$21.5M – $23.0M

Diluted EPS

$0.09 – $0.10

$0.35 – $0.37

Adjusted EBITDA2

$9.5M – $10.0M

$35.0M – $38.0M

Adj. EBITDA per diluted share2

$0.15 – $0.16

$0.57 – $0.61

Paysign expects to exit the third quarter of 2026 with 165–170

active patient affordability programs and 561–563 plasma centers.

2 The company is unable to provide a reconciliation

of forward-looking adjusted EBITDA, adjusted EBITDA per diluted share and adjusted EBITDA margin to the most directly comparable GAAP

measure, net income (and net income per diluted share), without unreasonable effort due to the variability, complexity and low visibility

of certain reconciling items. These items include, but are not limited to, stock-based compensation and other non-recurring items, which

could have a material impact on GAAP results.

Second Quarter 2026 Financial Results Conference Call Details

The company will hold a conference call at 5 p.m. Eastern time on Wednesday

August 5, 2026, to discuss its second quarter 2026 financial results. The conference call may include forward-looking statements. The

dial-in information for this call is 877.407.2988 (within the U.S.) and +1.201.389.0923 (outside the U.S.). A call replay will be available

until November 4, 2026, and can be accessed by dialing 877.660.6853 (within the U.S.) and +1.201.612.7415 (outside the U.S.), using passcode

13761445. An audio replay and a transcript of the call will be available following the call on the company's website, www.paysign.com,

under Investor Relations, Investor Resources. The earnings release and the financial and other statistical information discussed on the

call, including a reconciliation of any non-GAAP financial measures to the most directly comparable GAAP financial measures, are available

on the company's website, www.paysign.com, under Investor Relations, SEC Filings.

Forward-Looking Statements

Certain statements in this press

release may be considered forward-looking under federal securities laws, and we intend that such forward-looking statements be subject

to the safe harbor created thereby. All statements, besides statements of fact included in this release are forward-looking. Such forward-looking

statements include, among others, our belief that strong growth in our patient affordability business, steady performance in plasma donor

compensation, and disciplined execution across the company drove meaningful operating leverage and profitability, reinforcing the multiyear

strategy we have been building; our belief that with momentum across the business and a robust pipeline of opportunities, we intend to

remain focused on sustainable growth, continued margin expansion, and creating long-term value for shareholders; our belief that our patient

affordability solutions continue to resonate with pharmaceutical companies and that recent trends in our plasma business indicate improvement

from the high inventory levels that weighed on results throughout 2025; our belief that the strength we have seen through the first half

of the year, combined with the visibility into additional program launches and seasonal trends, supports our increased full-year outlook;

our belief that mix shift and expense discipline continue to drive gross and operating margin expansion; our belief that our balance sheet

supports continued investment and growth initiatives; our belief that our expectation that we will exit the third quarter of 2026 with

165–170 active patient affordability programs and 561–563 plasma centers; our belief that non-GAAP measures used by management

to gauge the operating performance of the business help investors better evaluate our past financial performance and potential future

results; and our expectations for total revenues, gross profit margins, operating expenses, depreciation and amortization expenses, stock-based

compensation expense, interest income, tax rate, fully diluted share count, net income, net income margin, Adjusted EBITDA and Adjusted

EBITDA margin for the third quarter and full-year 2026. We caution that these statements are qualified by important risks, uncertainties

and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors

include, among others, the inability to continue our current growth rate in future periods; the risk that we may not be able to add new

patient affordability programs or retain existing programs at anticipated rates; the risk that plasma center customers may switch to competing

providers or close centers, reducing our revenue; the risk that our outlook and guidance may not be achieved due to factors within or

outside our control; that a downturn in the economy could reduce our customer base and demand for our products and services, which could

have an adverse effect on our business, financial condition, profitability and cash flows; operating in a highly regulated environment;

failure by us or business partners to comply with applicable laws and regulations; changes in the laws, regulations, credit card association

rules or other industry standards affecting our business; changes in the regulatory or legislative environment affecting pharmaceutical

patient affordability or copay assistance programs, including potential restrictions on copay accumulator or maximizer programs; that

a data security breach could expose us to liability and protracted and costly litigation; risks related to the integration of acquisitions,

including the Gamma acquisition, and the realization of anticipated benefits therefrom; and other risk factors set forth in our Annual

Report on Form 10-K for the year ended December 31, 2025. Except to the extent required by federal securities laws, the company undertakes

no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

About Paysign, Inc.

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech

and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical

and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they

need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and

plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s

proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence,

enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer

support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers,

pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving

efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they

serve.

Contacts:

Investor Relations:

888.522.4810

paysign.com/investors

ir@paysign.com

Media Relations:

888.522.4850

pr@paysign.com

Paysign, Inc.

Condensed Consolidated Statements of Operation (Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Revenues

Plasma industry

$ 13,040,540

$ 10,743,924

$ 24,789,151

$ 20,153,804

Pharma industry

14,649,133

7,753,906

30,328,585

16,372,559

Other

562,398

580,523

1,172,759

1,150,139

Total revenues

28,252,071

19,078,353

56,290,495

37,676,502

Cost of revenues

10,355,048

7,323,188

20,174,527

14,230,509

Gross profit

17,897,023

11,755,165

36,115,968

23,445,993

Operating expenses

Selling, general and administrative

8,546,278

8,197,461

17,460,932

15,598,220

Depreciation and amortization

2,339,829

2,120,097

4,975,985

3,921,100

Total operating expenses

10,886,107

10,317,558

22,436,917

19,519,320

Income from operations

7,010,916

1,437,607

13,679,051

3,926,673

Other income

Interest income, net

894,203

605,160

1,695,066

1,367,358

Income before income tax provision

7,905,119

2,042,767

15,374,117

5,294,031

Income tax provision

1,148,582

655,006

3,178,662

1,320,170

Net income

$ 6,756,537

$ 1,387,761

$ 12,195,455

$ 3,973,861

Net income per share

Basic

$ 0.12

$ 0.03

$ 0.22

$ 0.07

Diluted

$ 0.11

$ 0.02

$ 0.20

$ 0.07

Weighted average common shares

Basic

55,864,262

54,228,027

55,265,671

53,903,829

Diluted

61,975,531

57,872,318

61,388,853

56,312,252

Paysign, Inc.

Condensed Consolidated Balance Sheets

June 30,

2026

(Unaudited)

December 31,

2025

(Audited)

ASSETS

Current assets

Cash

$ 27,372,858

$ 21,067,651

Restricted cash

149,109,681

143,917,060

Accounts receivable, net

103,167,960

72,191,994

Other receivables

345,228

926,529

Prepaid expenses and other current assets

3,030,661

1,953,717

Total current assets

283,026,388

240,056,951

Fixed assets, net

1,948,202

1,897,892

Intangible assets, net

20,838,025

22,346,213

Goodwill

4,487,637

Operating lease right-of-use asset

5,313,512

5,729,541

Deferred tax asset, net

1,375,842

1,734,969

Total assets

$ 316,989,606

$ 276,253,203

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable and accrued liabilities

$ 97,675,379

$ 70,542,803

Customer card funding

148,196,011

143,191,068

Operating lease liability, current portion

890,846

751,503

Other liabilities, current portion

1,686,507

1,863,116

Total current liabilities

248,448,743

216,348,490

Operating lease liability, long-term portion

4,819,451

5,273,891

Other liabilities, long-term portion

3,564,666

6,140,651

Total liabilities

256,832,860

227,763,032

Common stock; $0.001 par value; 150,000,000 shares authorized, 57,902,271 and 56,021,596 issued at June 30, 2026 and December 31, 2025, respectively

57,902

56,022

Additional paid-in capital

38,163,032

35,503,253

Treasury stock at cost, 1,459,689 and 934,708 shares, respectively

(5,339,254 )

(2,148,715 )

Retained earnings

27,275,066

15,079,611

Total stockholders’ equity

60,156,746

48,490,171

Total liabilities and stockholders’ equity

$ 316,989,606

$ 276,253,203

Paysign, Inc. Non-GAAP Measures

To supplement Paysign’s financial results presented on a GAAP

basis, we use non-GAAP measures that exclude from net income the following cash and non-cash items: interest, taxes, depreciation and

amortization and stock-based compensation. We believe these non-GAAP measures used by management to gauge the operating performance of

the business help investors better evaluate our past financial performance and potential future results. Non-GAAP measures should not

be considered in isolation or as a substitute for comparable GAAP accounting, and investors should read them in conjunction with the company’s

financial statements prepared in accordance with GAAP. The non-GAAP measures we use may be different from, and not directly comparable

to, similarly titled measures used by other companies.

“EBITDA” is defined as earnings before interest, taxes,

depreciation and amortization expense. “Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation

charges and change in fair value of contingent consideration.

EBITDA and Adjusted EBITDA are not intended to represent cash flows

from operations, operating income or net income as defined by U.S. GAAP as indicators of operating performances. Management cautions that

amounts presented in accordance with Paysign’s definition of Adjusted EBITDA may not be comparable to similar measures disclosed

by other companies because not all companies calculate Adjusted EBITDA in the same manner.

Paysign, Inc.

Adjusted EBITDA (Unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Reconciliation of Adjusted EBITDA to net income:

Net income

$ 6,756,537

$ 1,387,761

$ 12,195,455

$ 3,973,861

Income tax provision

1,148,582

655,006

3,178,662

1,320,170

Interest income, net

(894,203 )

(605,160 )

(1,695,066 )

(1,367,358 )

Depreciation and amortization

2,339,829

2,120,097

4,975,985

3,921,100

EBITDA

9,350,745

3,557,704

18,655,036

7,847,773

Stock-based compensation

1,252,256

954,400

2,536,259

1,626,718

Change in fair value of contingent consideration

(990,000 )

–

(990,000

–

Adjusted EBITDA

$ 9,613,001

$ 4,512,104

$ 20,201,295

$ 9,474,491

Adjusted EBITDA per share

Basic

0.17

0.08

0.37

0.18

Diluted

0.16

0.08

0.33

0.17

Weighted average common shares

Basic

55,864,262

54,228,027

55,265,671

53,903,829

Diluted

61,975,531

57,872,318

61,388,853

56,312,252

“EBITDA margin” is defined as earnings before interest,

income taxes, depreciation and amortization expense as a percentage of the company’s revenue and “Adjusted EBITDA margin”

reflects the adjustment to EBITDA margin to exclude stock-based compensation expense and change in fair value of contingent consideration

as a percentage of revenue. A reconciliation of net income margin to Adjusted EBITDA margin is provided in the table below.

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Reconciliation of adjusted EBITDA margin to net income margin:

Net income margin

23.9%

7.3%

21.7%

10.5%

Income tax provision

4.1%

3.4%

5.6%

3.5%

Interest income, net

(3.2% )

(3.0% )

(3.6% )

Depreciation and amortization

8.3%

11.1%

8.8%

10.4%

EBITDA margin

33.1%

18.6%

33.1%

20.8%

Stock-based compensation

4.4%

5.0%

4.5%

4.3%

Change in fair value of contingent consideration

(3.5% )

–

(1.8% )

–

Adjusted EBITDA margin

34.0%

23.7%

35.9%

25.1%

“Adjusted operating margin” is defined as income from operations

excluding fair value adjustment on contingent consideration as a percentage of the company’s revenue is provided in the table below.

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Reconciliation of adjusted operating margin to operating margin:

Operating margin

24.8%

7.5%

24.3%

10.4%

Change in fair value of contingent consideration

(3.5% )

–

(1.8% )

–

Adjusted operating margin

21.3%

7.5%

22.5%

10.4%

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity File Number

001-38623

Entity Registrant Name

PAYSIGN,

INC.

Entity Central Index Key

0001496443

Entity Tax Identification Number

95-4550154

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2615 St. Rose Parkway

Entity Address, City or Town

Henderson

Entity Address, State or Province

Entity Address, Postal Zip Code

89052

City Area Code

702

Local Phone Number

453-2221

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value per share

Trading Symbol

PAYS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration